Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

NCT04183192 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

FED

Sponsor class

Conditions

Healthy Subjects
Pharmacokinetics
Pharmacodynamics

Interventions

BIOLOGICAL: Mepolizumab
BIOLOGICAL: Mepolizumab
BIOLOGICAL: Mepolizumab
BIOLOGICAL: Mepolizumab
BIOLOGICAL: Reslizumab
BIOLOGICAL: Reslizumab
BIOLOGICAL: Reslizumab
BIOLOGICAL: Reslizumab
BIOLOGICAL: Placebo

Sponsor

Food and Drug Administration (FDA)

Collaborators

[object Object]